Case Report March 29, 2022

High-Dose Intranasal Bupropion Insufflation

Kara Termulo, BS; Miki Kiyokawa, MD; Gerald Busch, MD

Prim Care Companion CNS Disord 2022;24(2):21cr03056

Prim Care Companion CNS Disord 2022;24(2):21cr03056

To cite: Termulo K, Kiyokawa M, Busch G. High-dose intranasal bupropion insufflation. Prim Care Companion CNS Disord. 2022;24(2):21cr03056.
To share: https://doi.org/10.4088/PCC.21cr03056

© Copyright 2022 Physicians Postgraduate Press, Inc.

aJohn A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii
bDepartment of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii
cDepartment of Psychiatry, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii
*Corresponding author: Kara Termulo, BS, John A. Burns School of Medicine, 651 Ilalo St, Honolulu, HI 96813 ([email protected]).

 

Nasal insufflation of pulverized bupropion hydrochloride (bupropion) tablets has been previously reported as a growing public health problem and can induce effects similar to illicit stimulant drugs.1 Bupropion is approved by the US Food and Drug Administration for the management of depression and smoking cessation. Bupropion is a cathinone derivative that selectively blocks dopamine and norepinephrine reuptake.2,3 The current recommended maximum extended-release formulation is 450 mg/d via oral ingestion.3

We found 7 case reports4–10  in the literature that included the terms insufflation and bupropion. The maximum currently reported dose of insufflated bupropion is 2,100 mg/d.11 The effects of nasally insufflated bupropion varied among the 7 cases, ranging from a “mild buzz” to paranoia and seizure. Associated hyponatremia or suicidal ideation have not been recorded for this method of bupropion use. In this report, we present the case of a patient who reported intranasal insufflation of bupropion, up to 2,700 mg, every other day. The patient presented with hyponatremia and suicidal ideation secondary to bupropion-induced psychosis.

Case Report

A middle-aged man with a history of schizoaffective disorder and bipolar disorder was brought to the emergency department (ED) by the police after threatening to kill himself with a knife. The patient reported visual hallucinations, such as “seeing devils.” Both the suicidal ideation and hallucinations resolved by the time the addiction team was consulted. Upon interview, he reported crushing and insufflating 8 to 9 random combinations of 150-mg and 300-mg tablets of bupropion every other day for the past 3 years with a goal of experiencing euphoria. He obtained his bupropion prescription monthly from his psychiatrist (30 150-mg tablets and 30 300-mg tablets). Per his medical record, the bupropion prescription dosage remained the same for the past 6 to 7 years. The patient also has history of multiple suicide attempts, including stabbing himself, attempting to jump off a bridge, and brandishing multiple knives threatening to kill himself, as well as visual and auditory hallucinations, following bupropion insufflation for at least the past 6 years.

During the interview, the patient reported running out of the bupropion prescription within 10 days of filling it. He reported buying additional bupropion off the streets. He also had a history of infrequent methamphetamine and cannabis use, neither of which were his drug of choice, as well as a remote history of alcohol use. His family reported that the patient is quiet and calm with no baseline auditory or visual hallucinations; however, he becomes disruptive with bupropion insufflation. Laboratory results in the ED revealed a negative urine drug screen, except for cannabis, and a serum sodium level of 124 mEq/L. The patient was subsequently admitted to the hospital, and his hyponatremia resolved the next day following treatment with intravenous normal saline.

Discussion

Insufflation or “snorting” bypasses first-pass metabolism, resulting in a more rapid, elevated plasma concentration of the drug. The insufflation of crushed bupropion tablets is a more frequent abuse phenomenon in correctional settings.3,12 Our patient presented with hyponatremia, presumably from chronic bupropion use. A handful of case reports13–15 have shown that hyponatremia occurs in the elderly with standard oral bupropion administration. Although our patient did not have a seizure, hyponatremia placed this patient at an even higher risk of seizure, which is a known side effect of bupropion. Bupropion is also known to cause hallucinations, a rare side effect, in those with and without underlying psychosis. In our patient, the psychosis led to suicide attempts on multiple occasions. This case adds to the emerging literature documenting the abuse potential of bupropion, manifesting in hyponatremia and bupropion-induced psychosis leading to suicidal ideation.4–10

Published online: March 29, 2022.
Relevant financial relationships: None.
Funding/support: None.
Additional information: Information was de-identified to protect patient anonymity.

  1. Stall N, Godwin J, Juurlink D. Bupropion abuse and overdose. CMAJ. 2014;186(13):1015. PubMed CrossRef
  2. Dwoskin LP, Rauhut AS, King-Pospisil KA, et al. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev. 2006;12(3–4):178–207. PubMed CrossRef
  3. Lewis JC, Sutter ME, Albertson TE, et al. An 11-year review of bupropion insufflation exposures in adults reported to the California Poison Control System. Clin Toxicol (Phila). 2014;52(9):969–972. PubMed CrossRef
  4. Yoon G, Westermeyer J. Intranasal bupropion abuse: case report. Am J Addict. 2013;22(2):180–180. PubMed CrossRef
  5. Langguth B, Hajak G, Landgrebe M, et al. Abuse potential of bupropion nasal insufflation: a case report. J Clin Psychopharmacol. 2009;29(6):618–619. PubMed CrossRef
  6. Hill S, Sikand H, Lee J. A case report of seizure induced by bupropion nasal insufflation. Prim Care Companion J Clin Psychiatry. 2007;9(1):67–69. PubMed CrossRef
  7. Reeves RR, Ladner ME. Additional evidence of the abuse potential of bupropion. J Clin Psychopharmacol. 2013;33(4):584–585. PubMed CrossRef
  8. Khurshid KA, Decker DH. Bupropion insufflation in a teenager. J Child Adolesc Psychopharmacol. 2004;14(1):157–158. PubMed CrossRef
  9. Welsh CJ, Doyon S. Seizure induced by insufflation of bupropion. N Engl J Med. 2002;347(12):951. PubMed CrossRef
  10. Kim D, Steinhart B. Seizures induced by recreational abuse of bupropion tablets via nasal insufflation. CJEM. 2010;12(2):158–161. PubMed CrossRef
  11. Dhillon S, Yang LPH, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs. 2008;68(5):653–689. PubMed CrossRef
  12. Stassinos GL, Klein-Schwartz W. Bupropion “abuse” reported to US poison centers. J Addict Med. 2016;10(5):357–362. PubMed CrossRef
  13. Kate N, Grover S, Kumar S, et al. Bupropion-induced hyponatremia. Gen Hosp Psychiatry. 2013;35(6):681.e11–681.e12. PubMed CrossRef
  14. Kim CS, Choi JS, Bae EH, et al. Hyponatremia associated with bupropion. Electrolyte Blood Press. 2011;9(1):23–26. PubMed CrossRef
  15. Munjal S, Smolin Y. Bupropion induced hyponatremia in an elderly patient: a case report and review of the literature. Case Rep Psychiatry. 2016;2016:5103471. PubMed CrossRef